Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Zenz

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Leukemia|November 6, 2014
The impact of SF3B1 mutations in CLL on the DNA-damage responseG D Te Raa, I A M Derks, V Navrkalova, et al.
Leukemia|September 24, 2010
TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutationsT Zenz, D Vollmer, M Trbusek, et al.
Lancet (London, England)|October 5, 2010
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialM Hallek, K Fischer, G Fingerle-Rowson, et al.
Leukemia|August 15, 2017
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profilingE I Andersson, S Pützer, B Yadav, et al.
Leukemia|November 29, 2016
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemiaE Young, D Noerenberg, L Mansouri, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Leukemia|November 6, 2014
The impact of SF3B1 mutations in CLL on the DNA-damage responseG D Te Raa, I A M Derks, V Navrkalova, et al.
Leukemia|September 24, 2010
TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutationsT Zenz, D Vollmer, M Trbusek, et al.
Lancet (London, England)|October 5, 2010
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialM Hallek, K Fischer, G Fingerle-Rowson, et al.
Leukemia|August 15, 2017
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profilingE I Andersson, S Pützer, B Yadav, et al.
Leukemia|November 29, 2016
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemiaE Young, D Noerenberg, L Mansouri, et al.
Pageof 4